Article

Discovery of a CI-994 derivative as a dual modulator of class I HDACs and Wnt/β-catenin signaling for Alzheimer’s disease therapy

2026-05-05

Abstract excerpt

Alzheimer’s disease (AD) is a multifactorial disease with mixed pathologies. Consequentially, drugs targeting multiple pathological processes may offer synergistic benefits. While histone deacetylase (HDAC) inhibitors have demonstrated efficacy in alleviating AD-related pathologies in animal models, the neuroprotective Wnt/β-catenin signaling pathway remains compromised in AD brain. CI-994 is a class I HDAC inhibi...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f4468dec-4e64-5105-9db7-e79acda3b04c
DOI: 10.64898/2026.04.30.721954

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Discovery of a CI-994 derivative as a dual modulator of class I HDACs and Wnt/β-catenin signaling for Alzheimer’s disease therapyDOI 10.64898/2026.04.30.721954Read

Riluzole: a therapeutic strategy in Alzheimer’s disease by targeting the WNT/β-catenin pathwaySemantic proximity Read

HDAC3 as an Emerging Therapeutic Target for Alzheimer's Disease and other Neurological DisordersSemantic proximity Read

A Novel multifunctional 5,6-dimethoxy-indanone-chalcone-carbamate hybrids alleviates cognitive decline in Alzheimer’s disease by dual inhibition of acetylcholinesterase and inflammationSemantic proximity Read

Histone Deacetylase Inhibition in Alzheimer’s Disease: Molecular Mechanisms, Therapeutic Potential, and Future PerspectivesSemantic proximity Read

Identification of new BACE1 inhibitors for treating Alzheimer’s diseaseSemantic proximity Read

Liver-X receptor β-selective agonist CE9A215 regulates Alzheimer’s disease- associated pathology in a 3xTg-AD mouse modelSemantic proximity Read

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's diseaseSemantic proximity Read

Inhibition of CXXC5 function rescues Alzheimer’s disease phenotypes by restoring Wnt/β-catenin signaling pathwaySemantic proximity Read

Restoring Wnt/β-catenin signaling is a promising therapeutic strategy for Alzheimer’s diseaseSemantic proximity Read

Disease-modifying treatment with I2 imidazoline receptor ligand LSL60101 in an Alzheimer’s disease mouse model : A Comparative study with donepezilSemantic proximity Read

Discovering a novel dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitor and its impact on tau phosphorylation and amyloid-β formationSemantic proximity Read

Two sides of the same coin: Wnt signaling in neurodegeneration and neuro-oncology.Semantic proximity Read